ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Human Growth Hormone

Also written as “somatropin”, “Somatropin” and “PEG-somatropin”.

Its studies are mostly in Dwarfism, Pituitary · Turner Syndrome · Dwarfism · Growth Disorders · Genetic Diseases, Inborn, led by 15 companies.

Drug pageHuman Growth Hormone: every studyMany companies study it; this page follows only the 117 they lead. All 217 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Sep 13, 2005117 company-led studies, 5 open or runningNext primary completion: Apr 28, 2027 (phase 4)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Novo Nordiskits history only340 open or runningphase 4since Sep 13, 2005Feb 1, 2005none ahead
Changchun GeneScience Pharmaceuticalits history only194 open or runningphase 4since Nov 27, 2014Apr 21, 2011Apr 28, 2027phase 4 · NCT07691125
Merck KGaA, Darmstadt, Germany190 open or runningphase 4since Nov 18, 2005May 13, 2004none ahead
Pfizerits history only180 open or runningphase 4since Feb 5, 2007Sep 9, 2005none ahead
Eli Lillyits history only100 open or runningphase 4since Dec 15, 2005Sep 12, 2005none ahead
LG Chemits history only40 open or runningphase 4since Nov 10, 2016Dec 29, 2005none ahead
Daewoong Pharmaceuticalits history only20 open or runningphase 3since Jan 19, 2016Sep 23, 2011none ahead
Ferring Pharmaceuticalsits history only20 open or runningphase 3since Nov 7, 2005Nov 7, 2005none ahead
Hoffmann-La Rocheits history only20 open or runningphase 4since Dec 4, 2014Mar 11, 2004none ahead
Ipsenits history only20 open or runningphase 4since Aug 24, 2011Oct 5, 2005none ahead

Also a collaborator on its studies: Merck Serono S.A.S, France, Merck Serono Co., Ltd., China, Merck Serono S.P.A., Italy, Merck Serono S.A., Geneva, Merck, S.L., Spain and BioPartners.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Merck KGaA, Darmstadt, Germany only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

Before these, 3 studies since May 13, 2004.

  1. Nov 18, 2005Phase 4 study in Dwarfism, PituitaryNCT00256126 · 318 enrolled · Argentina, Australia, Austria and more
  2. Feb 16, 20062 phase 3 studies in Human Immunodeficiency Virus-associated Adipose Redistribution Syndrome (HARS)NCT00294164, NCT00294918
  3. Jun 20, 2007Phase 3 study in HIV InfectionsNCT00489528
  4. Jul 2, 2009Phase 3 study in FibromyalgiaNCT00933686 · 113 enrolled · Spain
  5. Dec 16, 2009Phase 1 study in Failure to ThriveNCT01034735 · 30 enrolled · Germany
  6. Feb 5, 2010Phase 4 study in Turner SyndromeNCT01066052 · 115 enrolled · France
  7. Feb 10, 20102 phase 3 studiesNCT01067352, NCT01077960
  8. Apr 23, 2010Phase 2 study in HypochondroplasiaNCT01111019 · 19 enrolled · France
  9. Jul 6, 2010Phase 4 study in DwarfismNCT01157793 · 34 enrolled
  10. Aug 22, 2010Phase 4 study in Dwarfism, PituitaryNCT01187550 · 214 enrolled
  11. Nov 5, 2010Phase 3 study in Dwarfism, PituitaryNCT01237340 · 59 enrolled · United States
  12. Jul 21, 2011Phase 3 study in Children Born With Serious Intra-uterine Growth RetardationNCT01400698 · 91 enrolled
  13. Nov 30, 2012Phase 3 study in Idiopathic Short StatureNCT01746862 · 90 enrolled · Korea, Republic of
  14. Mar 5, 2013Phase 4 study in Dwarfism, PituitaryNCT01806298 · 78 enrolled · Australia, Germany, Sweden and more
  15. Jul 28, 2021Named human growth hormoneINNProposed as its International Nonproprietary Name in WHO's List 125

TargetBeta

GHR →read by rule
“Growth hormone receptor agonist”ChEMBL 37, by rule

Other programs on GHR

ProgramCompanyFurthest phaseStudies
lonapegsomatropinruleascendis-pharma-endocrinology-division-a-sphase 36

Studies

All 19 Merck KGaA, Darmstadt, Germany leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT01806298Dwarfism, Pituitary · Australia, Germany, Sweden and more4CompletedMar 201678
NCT01746862Idiopathic Short Stature · Korea, Republic of3CompletedAug 201490
NCT01400698Children Born With Serious Intra-uterine Growth Retardation3CompletedFeb 201091
NCT01237340Dwarfism, Pituitary · United States3TerminatedDec 201159
NCT01187550Dwarfism, Pituitary4CompletedSep 2008214
NCT01157793Dwarfism4CompletedFeb 200534
NCT01111019Hypochondroplasia · France2CompletedJan 17, 201719
NCT01077960Human Immunodeficiency Virus-Associated Adipose Redistribution Syndrome · United States, Canada3CompletedJan 2006126
NCT01067352Infant, Small for Gestational Age · Italy3TerminatedJul 200925
NCT01066052Turner Syndrome · France4CompletedMar 31, 1999115
NCT01034735Failure to Thrive · Germany1CompletedAug 200830
NCT00933686Fibromyalgia · Spain3CompletedJul 2010113
NCT00489528HIV Infections3Completed
NCT00294918Human Immunodeficiency Virus-associated Adipose Redistribution Syndrome (HARS)3CompletedFeb 2003142
NCT00294164Human Immunodeficiency Virus-associated Adipose Redistribution Syndrome (HARS)3CompletedMay 2002245
NCT00256126Dwarfism, Pituitary · Argentina, Australia, Austria and more4CompletedSep 30, 2007318
NCT00249821Small Gestational Age (SGA)3CompletedSep 30, 200722
NCT00109733Dwarfism, Pituitary · United States3CompletedJun 200631
NCT00082628HIV Infections · United States, Canada3CompletedSep 28, 2005326

How it is read

Names in the registry

  • “somatropin”, 52 entries
  • “Somatropin”, 27 entries
  • “PEG-somatropin”, 13 entries
  • “Saizen®”, 6 entries
  • “Genotropin”, 5 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.